[A22-97] Nivolumab (urothelial carcinoma, adjuvant) - Addendum to Commission A22-53
Last updated 20.10.2022
Project no.:
A22-97
Commission:
Commission awarded on 06.09.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with muscle invasive urothelial carcinoma with tumour cell PD-L1 expression ≥ 1%, who are at high risk of recurrence after complete resection
Unchanged after addendum:
- Patients who are eligible for cisplatin-containing therapy for adjuvant treatment: added benefit not proven
- Patients who are not eligible for cisplatin-containing therapy for adjuvant treatment: hint of minor added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-53 | Nivolumab (urothelial carcinoma, adjuvant) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-10-20 A G-BA decision was published.